Published in Medicine and Law Weekly, April 8th, 2005
John DeBernardis, APNS president & CEO said "The company is pursuing development of second generation tests for diagnosing Alzheimer's disease (AD), and the patent recently awarded supports one of the key methodologies we are focused on."
He said, "Our goal is to develop an accurate blood test that can detect AD at very early stages. A blood test could be suitable for once-a-year screening for all adults over the age of 65. We are very pleased by this addition to our expanding...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly